Company news: RealAge and HealthPrize; AstraZeneca and Daiichi Sankyo; Shire

Share this article:
RealAge and HealthPrize are partnering to measure the effectiveness of HealthPrize's adherence program on RealAge members taking asthma meds. The program, which will launch in June, aims to assess patient preferences for incentives – whether earning points or receiving rebates is a bigger motivator, for example. The companies said preliminary results suggest that consumers might prefer earning points over rebates. RealAge, which recently published strong results from an internal employee weight loss program, will use the findings to develop additional programs for its members on specific medications, while HealthPrize will use the data to fine-tune its adherence offering.

AstraZeneca signed a co-promotion agreement for denosumab in Japan with Daiichi Sankyo, pending approval of the drug for the treatment of bone disorders stemming from bone metastasis. Daiichi Sankyo acquired rights to the drug in Japan from Amgen in 2011 and filed for approval there in 2010.

Shire is launching a scholarship program for college students with ADHD. The Shire ADHD Scholarship Program includes a monetary award and a prepaid year of ADHD coaching services provided in partnership with Seattle nonprofit the Edge Foundation make the transition to college, vocational or technical school.
Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.